Real Life Data for Glecaprevir/Pibrentasvir: A Single-Center Study

Autor:	Fatma Çölkesen, Esma Eroğlu, Fatma Kacar, Şule Özdemir Armağan, Arzu Tarakçi
Rok vydání:	2021
Předmět:	Computer science Real-time computing Medicine General Medicine Glecaprevir Glecaprevir / pibrentasvir Single Center Real life data Pibrentasvir Chronic Hepatitis C Direct-Acting Antiviral Agent Glecaprevir Pibrentasvir Tıp
Zdroj:	Volume: 2, Issue: 1 14-18 Archives of Current Medical Research
ISSN:	2717-9788
Popis:	Background: Licensing of next-generation direct-acting antiviral agents (DAA) has revolutionized the treatment of Hepatitis C Virus (HCV) infection. These agents are important due to their high virological efficacy, high resistance barrier, short duration of treatment, and rare serious side effects. The purpose of our study was to present real-life data of chronic hepatitis C (CHC) infected patients with genotypes 2 and 3 who were treated with glecaprevir/pibrentasvir regimen.Methods: Glecaprevir/pibrentasvir treatment was initiated in 127 patients infected with CHC genotype 2 and 3. Patients received glecaprevir/pibrentasvir (100 mg/40 mg) orally in the form of three tablets once a day as per recommendations of the Republic of Turkey, Ministry of Health. In the assessments of patients at the time of diagnosis and following DAA use, virological response criteria HCV-RNA value was
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::878a14e53f2ffcd727429ba06bad4db8 https://doi.org/10.47482/acmr.2021.9 Zobrazit plný text záznamu